Inclusion Criteria:

          -  Patients with confirmed diagnosis of histologic grade 2 neuroendocrine tumor with
             unresectable liver metastases (primary tumor or other extrahepatic disease may be
             present)

          -  Patients with at least one measurable liver metastases, with size > 1cm (RECIST
             criteria)

          -  Patients with liver dominant disease defined as ≥50% tumor body burden confined to the
             liver

          -  Liver tumor burden does not exceed 50% of the liver volume

          -  Patent main portal vein

          -  At least 4 weeks since last administration of last chemotherapy and /or radiotherapy

          -  Age >18 years.

          -  Life expectancy of greater than 6 months.

          -  ECOG performance status 0-2.

          -  Adequate liver function as measured by: Total bilirubin ≤ 2.0mg/dl, ALT, AST ≤5 times
             ULN, albumin ≥2.5g/dl.

          -  Patients must have adequate organ and marrow function as defined below:

          -  platelets >100,000/mcL (may be corrected by transfusion)

          -  serum creatinine < 2.0 mg/dl

          -  INR <1.6, (may be corrected by transfusion)

          -  Ability to understand and the willingness to sign a written informed consent document.

          -  Women of child bearing potential and fertile men are required to use effective
             contraception (negative urine or serum βHCG for women of child-bearing age)

        Exclusion Criteria:

          -  Contraindications to capecitibine or temozolomide

          -  Contraindicated for both contrast-enhanced MRI and CT

          -  Patients previously treated with transarterial embolization (with or without
             chemotherapy) or with radioembolization (Y-90 microspheres)

          -  Contraindication for radioembolization procedures:

          -  excessive hepatopulmonary shunt as determined by the investigator

          -  inability to deliver Y90 microspheres without risk of non-target embolization of
             extra-hepatic structures

          -  Subjects consenting to the trial who fail their simulation angiography will be removed
             from the study and replaced.

          -  Patients may not be receiving any other investigational agents.

          -  Absolute contraindication to intravenous iodinated contrast (Hx of significant
             previous contrast reaction, not mitigated by appropriate pre-medication).

          -  Choledochoenteric anastomosis, transpapillary stent or sphincterotomy of duodenal
             papilla;

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

          -  Pregnant and lactating women are ineligible